CZEN-002 had been in phase II clinical trials for the treatment of vulvovaginal candidiasis. However, no recent development has been reported.
It was developed by Zengen, Abiogen Pharma and Lee's pharmaceuticals.
|CAS No.||457605-12-8 (CZEN-002);|
|Chemical Name||L-Valinamide, N-acetyl-L-cysteinyl-L-lysyl-L-prolyl-, bimol. (1®1')-disulfide|
|CZEN-002 （Free Acid/Base）Parameters：|
|*：Calculated by ACD/Labs software V11.02.|